These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 2495144)
21. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. Divrik RT; Yildirim U; Zorlu F; Ozen H J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720 [TBL] [Abstract][Full Text] [Related]
22. Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. Jauhiainen K; Alfthan O Br J Urol; 1987 Jul; 60(1):54-9. PubMed ID: 3113524 [TBL] [Abstract][Full Text] [Related]
23. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439 [TBL] [Abstract][Full Text] [Related]
24. [Prophylactic intravesical instillation therapy with adriamycin (ADM) and mitomycin C (MMC) in patients with superficial bladder cancer]. Ozaki Y; Tsushima T; Nasu Y; Akagi T; Obama T; Matsumura Y; Ohmori H Nihon Hinyokika Gakkai Zasshi; 1986 Sep; 77(9):1493-500. PubMed ID: 3100850 [No Abstract] [Full Text] [Related]
25. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. Huland H; Otto U; Droese M; Klöppel G J Urol; 1984 Jul; 132(1):27-9. PubMed ID: 6427483 [TBL] [Abstract][Full Text] [Related]
26. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. Soloway MS; Jordan AM; Murphy WM Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268 [TBL] [Abstract][Full Text] [Related]
27. [Recurrence rate in adjuvant local chemotherapy of bladder cancer with mitomycin C]. Flüchter SH; Harzmann R; Erdmann D; Bichler KH Helv Chir Acta; 1982 Aug; 49(3-4):349-52. PubMed ID: 6813293 [No Abstract] [Full Text] [Related]
28. Intravesical instillation of mitomycin-C in 242 patients with superficial bladder cancer at high risk of recurrence: long-term results. Hurle R; Manzetti A; Losa A; Micheli E; Ranieri A; Chinaglia D; Lembo A Urol Int; 1998; 61(4):220-6. PubMed ID: 10364753 [TBL] [Abstract][Full Text] [Related]
29. Short schedule intravesical mitomycin preceding transurethral resection for recurrent Ta-T1, G1-G2 bladder cancer. Maffezzini M; Simonato A; Lodolo C; Raber M; Carmignani G Tumori; 1995; 81(3):191-3. PubMed ID: 7571026 [TBL] [Abstract][Full Text] [Related]
30. Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup. Stricker PD; Grant AB; Hosken BM; Taylor JS J Urol; 1990 Jan; 143(1):34-5; discussion 35-6. PubMed ID: 2104637 [TBL] [Abstract][Full Text] [Related]
31. Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours. Hetherington JW; Newling DW; Robinson MR; Smith PH; Adib RS; Whelan P Br J Urol; 1987 Mar; 59(3):239-41. PubMed ID: 3105631 [TBL] [Abstract][Full Text] [Related]
32. Prophylactic treatment for superficial bladder cancer following transurethral resection. Hirao Y; Okajima E; Ohara S; Ozono S; Hiramatsu T; Yoshida K; Yamada K; Aoyama H; Hashimoto M; Watanabe S Cancer Chemother Pharmacol; 1987; 20 Suppl():S85-90. PubMed ID: 3117402 [TBL] [Abstract][Full Text] [Related]
33. A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. Harrison GS; Green DF; Newling DW; Richards B; Robinson MR; Smith PH Br J Urol; 1983 Dec; 55(6):676-9. PubMed ID: 6418263 [TBL] [Abstract][Full Text] [Related]
34. Intravesical mitomycin C for carcinoma in situ of the urinary bladder. Hellsten S; Månsson W; Henrikson H; Idwall I; Lindholm K; Mikulowski P; Mårtensson S; Oldbring J Scand J Urol Nephrol; 1990; 24(1):35-8. PubMed ID: 2108491 [TBL] [Abstract][Full Text] [Related]
35. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080 [TBL] [Abstract][Full Text] [Related]
36. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. Rintala E; Jauhiainen K; Kaasinen E; Nurmi M; Alfthan O J Urol; 1996 Jul; 156(1):56-9; discussion 59-60. PubMed ID: 8648837 [TBL] [Abstract][Full Text] [Related]
37. Plasma levels during intravesical instillation of mitomycin-C. Kurth KH; de Wall JG; van Oosterom AT; de Jong EA; Tjaden UR Prog Clin Biol Res; 1985; 185B():81-93. PubMed ID: 3929272 [No Abstract] [Full Text] [Related]